<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00071552</url>
  </required_header>
  <id_info>
    <org_study_id>IXR-402-4-196</org_study_id>
    <nct_id>NCT00071552</nct_id>
  </id_info>
  <brief_title>Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients</brief_title>
  <official_title>Evaluation of Clinical Efficacy of HFA-Propelled Beclomethasone Dipropionate Metered-Dose Inhaler Versus Fluticasone Propionate Multidose Dry Powder Inhaler on Small Airways in Poorly Controlled Asthmatic Adolescent and Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products, R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of Beclomethasone dipropionate
      HFA on small airways compared to Fluticasone propionate powder for inhalation administered
      twice daily to poorly controlled asthmatics.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Very poor enrollment
  </why_stopped>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in post-inhalation percent-predicted FEF 25-75 (%) from baseline (week 0) to week 12</measure>
    <time_frame>Final Visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean and mean change from pre-dose to 15-minute post-dose in percent predicted FEV1 (%) at week 12</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Qvar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qvar 160 mcg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flovent Diskus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flovent Diskus 200 mcg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qvar</intervention_name>
    <description>Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks</description>
    <arm_group_label>Qvar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flovent Diskus</intervention_name>
    <description>Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks</description>
    <arm_group_label>Flovent Diskus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Poorly controlled asthma;

          -  Average use of over 2 puffs of albuterol per day in the previous 7 days OR Having
             symptoms of asthma on 5 of the last 7 days OR Awakening at night due to asthma at
             least once in the previous 7 days OR Having been treated with a course of oral or
             intravenous steroids at least once in the last 3 months.

        Exclusion Criteria:

          -  Subjects receiving escalating doses of immunotherapy, oral immunotherapy or short
             course (rush) immunotherapy for rhinitis;

          -  Requires beta-blockers, MAO inhibitors, tricyclic antidepressants, oral or intranasal
             anticholinergics;

          -  History and/or presence of any non-asthmatic acute or chronic lung disease, including
             but not limited to bronchitis, emphysema, active tuberculosis, bronchiectasis or
             cystic fibrosis;

          -  History and/or presence of any clinically significant cardiovascular disease,
             clinically significant hepatic, renal, or endocrine dysfunction, stroke, uncontrolled
             diabetes, hyperthyroidism, convulsive disorders, neoplastic disease other than basal
             cell carcinoma, and significant psychiatric disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2003</study_first_submitted>
  <study_first_submitted_qc>October 28, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2003</study_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <keyword>Poorly Controlled Asthma</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

